Skip to content

Transcranial Photobiomodulation with Multiple Interventions in Children with Attention-Deficit/Hyperactivity Disorder

Transcranial Photobiomodulation with Multiple Interventions in Children with Attention-Deficit/Hyperactivity Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126126
Enrollment
Unknown
Registered
2026-06-04
Start date
2025-10-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder

Interventions

Sham session:Sham session
Active session:transcranial photobiomodulation

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age must be >= 6 years and <= 18 years; 2. Clinically diagnosed with ADHD by a psychiatrist; 3.Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 4. M.I.N.I. KID interview shows only ADHD, with no other comorbidities; 5. Able to cooperate with transcranial photobiomodulation. 6. The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder; 2. Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc. 3. Presence of significant structural brain abnormalities on imaging studies; 4. Presence of severe neurological diseases with a clear family history or potential risk; 5. Presence of metal implants or a pacemaker, or holes or fractures in the skull; 6. Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks; 7. Raven's Progressive Matrices IQ score < 85.

Design outcomes

Primary

MeasureTime frame
ADHD-related clinical symptom indicators (SNAP-IV scores);

Secondary

MeasureTime frame
Reaction time and accuracy;SDSC, BAS/BIS scales, subjective sensation scale scores;

Countries

China

Contacts

Public ContactCao Aihua

Qilu Hospital of Shandong University

xinercah@163.com+86 18560086317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026